Orient Pharma CoROCO:4166 61 Days Inventory is 174.59 as of Dec. 2025, which is 16% above its 10-year median of 150.31. GuruFocus rates ROCO:4166 with a GF Score™ of 61/100 and a GF Value™ of NT$45.13 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 919 Drug Manufacturers companies, Orient Pharma Co ranks worse than 59.52% on this metric.
The historical rank and industry rank for Orient Pharma Co's Days Inventory or its related term are showing as below:
ROCO:4166'
s Days Inventory Range Over the Past 10 Years
Min: 82.51 Med: 150.31 Max: 187.02
Current: 187.02
During the past 13 years, Orient Pharma Co's highest Days Inventory was 187.02. The lowest was 82.51. And the median was 150.31.
ROCO:4166's Days Inventory is ranked worse than 59.52% of 919
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs ROCO:4166: 187.02
Orient Pharma Co's Days Inventory
declined
from Dec. 2024 (176.91) to Dec. 2025 (174.59).
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Orient Pharma Co's Inventory Turnover for the
three
months ended in Dec. 2025 was 0.52.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Orient Pharma Co's Inventory-to-Revenue for the
three
months ended in Dec. 2025 was 0.76.
Orient Pharma Co (ROCO:4166) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Orient Pharma Co's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Orient Pharma Co's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Orient Pharma Co Days Inventory Related Terms
Orient Pharma Co Days Inventory Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orient Pharma Co (ROCO:4166) has a Days Inventory of 174.59 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Orient Pharma Co and its competitors. This is 16% above median its historical median of 150.31. Over the past decade, Orient Pharma Co's Days Inventory has ranged from 82.51 to 187.02. According to the industry distribution chart, Orient Pharma Co ranks #547 out of 919 companies in the Drug Manufacturers industry, placing it in the top 59.5%.
Is Orient Pharma Co's Days Inventory too high?
Orient Pharma Co's current Days Inventory of 174.59 is 16% above median its 10-year median of 150.31. Over the past 10 years, this metric has ranged from a low of 82.51 to a high of 187.02. The Drug Manufacturers industry median Days Inventory is 164.48. Orient Pharma Co's value of 174.59 is 6.1% above this industry median. Based on the distribution chart, Orient Pharma Co ranks #547 out of 919 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orient Pharma Co has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #547 out of 919 companies for Days Inventory. This places Orient Pharma Co in the lower half of its industry. The industry median Days Inventory is 164.48. Orient Pharma Co's value of 174.59 is 6.1% above this benchmark. Historically, Orient Pharma Co's own Days Inventory has ranged from 82.51 to 187.02 over the past decade. While the company's 10-year median is 150.31 vs. the industry median of 164.48, Orient Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current Days Inventory of 174.59 is 6.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Days Inventory is 174.59, which is 16% above median its own 10-year median of 150.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.13, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current Days Inventory is 174.59, which is 16% above median its 10-year median of 150.31 and 6.1% above the Drug Manufacturers industry median of 164.48. Orient Pharma Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Days Inventory is 174.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.13.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Days Inventory: 174.59 (16% above median its 10-year median of 150.31)
GF Value™: NT$45.13 vs. price of NT$27.20 (39.7% below fair value)
Industry Position: 6.1% above the Drug Manufacturers median (#547 of 919)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
61GF Score
Get the complete analysis for ROCO:4166
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
